Thus, for the patients who have no mutation in BMPR2, i.e., around 30% of HPAH and 60–90% of IPAH, another approach, which is practical for multiple genes, is necessary. This evidence concerns the gene BMPR2 and idiopathic pulmonary arterial hypertension.